Postmenopausal Osteoporosis: Latest Guidelines

• Autores: Rod-Marianne Arceo-Mendoza, Pauline M. Camacho
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 50, Nº. 2, 2021 (Ejemplar dedicado a: Updates on Osteoporosis), págs. 167-178
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Osteoporosis is a disease characterized by increased bone turnover and decreased bone mass with associated skeletal fragility, resulting in an increased risk of fracture.1 It is a well-defined and growing public health problem. The National Osteoporosis Foundation estimates that 10.2 million Americans have osteoporosis and that an additional 43.4 million have low bone mass. It is estimated that by 2030, the number of adults with osteoporosis and low bone mass will increase to 71 million.2 More than 2 million osteoporosis-related fractures occur annually in the United States. Approximately 1 in 2 White women and 1 in 5 men will experience an osteoporotic-related fracture in their lifetime. By 2025, the burden in the country is projected to increase by almost 50% to more than 3 million fractures and US$253 billion per year.